M&A Deal Summary |
|
|---|---|
| Date | 2023-10-10 |
| Target | Palette Life Sciences |
| Sector | Life Science |
| Buyer(s) | Teleflex |
| Deal Type | Add-on Acquisition |
| Deal Value | 600M USD |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1943 |
| Sector | Medical Products |
| Employees | 14,100 |
| Revenue | 3.0B USD (2024) |
Teleflex is a provider of medical technology products that enhance clinical benefits, improve patient and provider safety and reduce total procedural costs. The Company primarily designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. Teleflex markets and sells its products to hospitals and healthcare providers worldwide through a combination of our direct sales force and distributors. Teleflex was founded in 1943 and is based in Wayne, Pennsylvania.
| DEAL STATS | # |
|---|---|
| Overall | 28 of 29 |
| Sector: Life Science M&A | 2 of 2 |
| Type: Add-on Acquisition M&A Deals | 24 of 24 |
| Country: Sweden M&A | 1 of 1 |
| Year: 2023 M&A | 1 of 1 |
| Size (of disclosed) | 5 of 14 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-08-22 |
Standard Bariatrics
Cincinnati, Ohio, United States Standard Bariatrics is a surgical procedure company focused on the innovative development and commercialization of medical devices. Driven by a passionate group of surgical innovators, the company continues to release surgical solutions designed to address significant market opportunities. Standard Bariatrics was founded in 2014 and is based in Cincinnati, Ohio. |
Buy | $170M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-02-27 |
Biotronik s Vascular Intervention Business
Berlin, Germany Biotronik's Vascular Intervention Business consists of a comprehensive and differentiated portfolio for coronary and peripheral interventions performed in the cath lab and interventional radiology suites. In coronary vascular interventions, key products include the Pantera Lux Drug-Coated Balloon Catheter, the novel PK Papyrus Covered Coronary Stent for acute coronary artery perforations, and the Orsiro Mission Drug Eluting Stent, an ultrathin drug-eluting stent with differentiated clinical features. |
Buy | €760M |
